TC Biopharm (Holdings) Plc
TCBPY
$0.28
$0.000.00%
OTC PK
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -53.85% | 27.47% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -53.85% | 27.47% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -53.85% | 27.47% |
| SG&A Expenses | -5.87% | -14.34% | -20.58% | -16.45% | -10.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -72.92% | 675.46% | -- | -- | -- |
| Total Operating Expenses | -15.42% | -8.87% | -9.40% | -7.65% | -5.42% |
| Operating Income | -3.97% | -15.39% | -18.30% | -2.92% | 10.70% |
| Income Before Tax | -312.93% | -151.03% | -142.95% | 22.03% | 77.40% |
| Income Tax Expenses | 62.63% | 52.54% | 36.13% | 28.20% | 5.26% |
| Earnings from Continuing Operations | -769.43% | -316.76% | -398.13% | 19.45% | 88.26% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -769.43% | -316.76% | -398.13% | 19.45% | 88.26% |
| EBIT | -3.97% | -15.39% | -18.30% | -2.92% | 10.70% |
| EBITDA | -5.48% | -17.61% | -20.66% | -4.20% | 10.17% |
| EPS Basic | -- | -- | -- | -- | -- |
| Normalized Basic EPS | -- | -- | -- | -- | -- |
| EPS Diluted | -- | -- | -- | -- | -- |
| Normalized Diluted EPS | -- | -- | -- | -- | -- |
| Average Basic Shares Outstanding | -- | -- | -- | -- | -- |
| Average Diluted Shares Outstanding | -- | -- | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |